scholarly journals Non-Small Cell Lung Carcinoma: Cyclin D1, bcl-2, p53, Ki-67 and Her-2 Proteins Expression in Resected Tumors

2007 ◽  
Vol 7 (3) ◽  
pp. 205-211 ◽  
Author(s):  
Svjetlana Radović ◽  
Mirsad Babić ◽  
Mirsad Dorić ◽  
Ajna Hukić ◽  
Suada Kuskunović ◽  
...  

The aim of this study was to investigate expression of cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins in 14 cases of non-small cell lung cancer and to establish their correlation to classical clinico-pathological findings, and alleged prognostic value to estimate biological potential of tumor. Retrospective pilot study of the surgically treated non-small cell lung cancer biopsy specimen, paraffin embedded, used immu-nohistochemical method to demonstrate expression of cyclin D1, bcl-2, p53, Ki-67 and HER-2. Protein quantification was performed by the semi-quantitative method. Achieved results were correlated with classical clinico-pathological parameters, like tumor size, histological type, differentiation level, presence ofvascular invasion and metastasis in regional lymph nodes. Out of 14 cases of non-small cell lung cancer, squamous cell carcinoma was found in 7 patients, giant cell carcinoma in 3, adenocarcinoma in 2, and 1 case of pleomorphic and mucoepidermoid carcinoma. Expression of cyclin D1 was not found, while expression of HER-2 and bcl-2 protein was established in one cases each. p53 expression was noted in 8 cases (57,1%). Statistically positive significant correlation (p<0,05) was found among: presence of lympho-vascular invasion to tumor tissue and appearance of nodal metastasis; proliferation Ki-67 index and level of tumor differentiation, i.e. size of tumor. Other investigated parameters showed no significant statistically dependence. p53 expression was not correlated to any of the investigated parameters what might imply the possibility that there is an independent pathway of this protein expression. Negative expression of bcl-2 protein points out to possibility that it is not included into process of tumor apoptosis, as well as that proteins cyclin D1 and HER-2 are not included into processes of the tumor genesis. Since the prolif-erative activity of the tumor, measured by the expression of Ki-67, is correlated to the gradus and size of the tumor mass, Ki-67 protein can be of a prognostic value to determine biological potential of non-small cell lung cancer.

2000 ◽  
Vol 102 (3) ◽  
pp. 323-338 ◽  
Author(s):  
Viet Nhung Nguyen ◽  
Pavel Miřejovský ◽  
Tomáš. Miejovský ◽  
Libuše Melínová ◽  
Václav Mandys

Tumor Biology ◽  
2014 ◽  
Vol 35 (6) ◽  
pp. 5735-5740 ◽  
Author(s):  
Hee Kyung Ahn ◽  
Minkyu Jung ◽  
Seung-Yeon Ha ◽  
Jae-Ik Lee ◽  
Inkeun Park ◽  
...  

2006 ◽  
Vol 21 (2) ◽  
pp. 81-87 ◽  
Author(s):  
J. Fijołek ◽  
E. Wiatr ◽  
E. Rowińska-Zakrzewska ◽  
D. Giedronowicz ◽  
R. Langfort ◽  
...  

The aim of the study was to investigate a relation between p53 and HER2/neu expression in resected lung tumors and the response of those tumors to neoadjuvant chemotherapy. The study population included 67 consecutive patients with non-small cell lung cancer (NSCLC) in stage II or III who were operated on at the Institute of Tuberculosis, Warsaw, Poland, between 20 April 2001 and 10 March 2003. All patients received two cycles of chemotherapy consisting of cisplatin and vinorelbine prior to the operation. The response to therapy was assessed as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD), on the basis of CT scans performed before and after neoadjuvant chemotherapy. p53 and HER2/neu protein expression were evaluated by immunohistochemistry (IHC) using antibodies against p53 (clone PAb 1801, Novocastra) and against HER2/neu (Dako) in paraffin-embedded specimens of tumors. A response to therapy (CR+PR) was observed in 27 patients, while 40 patients (SD+PD) were regarded as resistant to therapy. Resistance was observed significantly more often in tumors above 3 cm in diameter. p53 expression was found in 16 tumors (23.9%) and HER2/neu in 26 tumors (38.8%). We observed a nonsignificant tendency to chemoresistance in tumors with HER-2/neu overexpression and also in tumors with p53 overexpression. If we consider HER-2/neu and p53 together, chemoresistance was observed statistically significantly more often when one or both markers were positive (p<0.05). This significance was independent of tumor size.


Lung Cancer ◽  
1997 ◽  
Vol 18 ◽  
pp. 155
Author(s):  
Marchetti ◽  
C. Doglioni ◽  
M. Barbareschi ◽  
F. Buttitta ◽  
S. Pellegrini ◽  
...  

2016 ◽  
Vol 50 (1) ◽  
pp. 24-30 ◽  
Author(s):  
Soyeon Park ◽  
Eunsub Lee ◽  
Seunghong Rhee ◽  
Jaehyuk Cho ◽  
Sunju Choi ◽  
...  

2002 ◽  
Vol 8 (3) ◽  
pp. 222-233 ◽  
Author(s):  
Jeffrey M. Pugsley ◽  
Rodney A. Schmidt ◽  
Hubert Vesselle

Sign in / Sign up

Export Citation Format

Share Document